JP2013510825A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510825A5 JP2013510825A5 JP2012538350A JP2012538350A JP2013510825A5 JP 2013510825 A5 JP2013510825 A5 JP 2013510825A5 JP 2012538350 A JP2012538350 A JP 2012538350A JP 2012538350 A JP2012538350 A JP 2012538350A JP 2013510825 A5 JP2013510825 A5 JP 2013510825A5
- Authority
- JP
- Japan
- Prior art keywords
- het
- nhso
- cor
- con
- hal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000004432 carbon atom Chemical group C* 0.000 claims 17
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 9
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 7
- 229910052757 nitrogen Inorganic materials 0.000 claims 7
- 125000002619 bicyclic group Chemical group 0.000 claims 6
- 125000002950 monocyclic group Chemical group 0.000 claims 5
- 229920006395 saturated elastomer Polymers 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004434 sulfur atom Chemical group 0.000 claims 3
- -1 U includes X 5 Chemical group 0.000 claims 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000000209 Isaacs syndrome Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000000185 Localized scleroderma Diseases 0.000 claims 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010072359 Neuromyotonia Diseases 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010000269 abscess Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 208000004631 alopecia areata Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 201000001981 dermatomyositis Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 210000000106 sweat gland Anatomy 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09175933 | 2009-11-13 | ||
| EP09175933.2 | 2009-11-13 | ||
| US26185409P | 2009-11-17 | 2009-11-17 | |
| US61/261,854 | 2009-11-17 | ||
| PCT/EP2010/067412 WO2011058149A1 (en) | 2009-11-13 | 2010-11-12 | Tricyclic pyrazol amine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013510825A JP2013510825A (ja) | 2013-03-28 |
| JP2013510825A5 true JP2013510825A5 (enExample) | 2014-01-09 |
| JP5735526B2 JP5735526B2 (ja) | 2015-06-17 |
Family
ID=41796476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538350A Active JP5735526B2 (ja) | 2009-11-13 | 2010-11-12 | 三環式ピラゾールアミン誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9073940B2 (enExample) |
| EP (1) | EP2499146B1 (enExample) |
| JP (1) | JP5735526B2 (enExample) |
| KR (1) | KR20130049766A (enExample) |
| CN (1) | CN102695710B (enExample) |
| AR (1) | AR078979A1 (enExample) |
| AU (1) | AU2010317883B2 (enExample) |
| CA (1) | CA2778174C (enExample) |
| EA (1) | EA201290305A1 (enExample) |
| ES (1) | ES2607952T3 (enExample) |
| IL (1) | IL219602A (enExample) |
| MX (1) | MX2012005518A (enExample) |
| WO (1) | WO2011058149A1 (enExample) |
| ZA (1) | ZA201202641B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2595623B1 (en) | 2010-07-19 | 2018-02-28 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Use of delta tocopherol for the treatment of lysosomal storage disorders |
| DE102011055815A1 (de) | 2011-11-29 | 2013-05-29 | Aicuris Gmbh & Co. Kg | Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung |
| PL2790705T3 (pl) | 2011-12-15 | 2018-06-29 | Novartis Ag | Zastosowanie inhibitorów czynności lub funkcji PI3K |
| DE102012016908A1 (de) | 2012-08-17 | 2014-02-20 | Aicuris Gmbh & Co. Kg | Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung |
| WO2014078573A2 (en) | 2012-11-16 | 2014-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tocopherol and tocopheryl quinone derivatives as correctors of lysosomal storage disorders |
| WO2014121901A1 (en) | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Polymorphic forms |
| CN105473596B (zh) * | 2013-06-24 | 2019-04-30 | 默克专利有限公司 | 用作卵泡刺激素受体调节剂的吡唑化合物及其用途 |
| WO2015196335A1 (en) | 2014-06-23 | 2015-12-30 | Tocopherx, Inc. | Pyrazole compounds as modulators of fshr and uses thereof |
| WO2017033019A1 (en) | 2015-08-26 | 2017-03-02 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) | Condensed tricyclic compounds as protein kinase inhibitors |
| JP7101177B2 (ja) | 2017-01-10 | 2022-07-14 | バイエル・アクチエンゲゼルシヤフト | 有害生物防除剤としてのヘテロサイクレン誘導体 |
| MX2019008230A (es) | 2017-01-10 | 2019-10-24 | Bayer Ag | Derivados heterociclicos como agentes de control de plagas. |
| CN108434150B (zh) * | 2018-02-09 | 2020-03-10 | 天津医科大学总医院 | Zstk474用于制备ean治疗药物的应用 |
| EP3608326A1 (en) * | 2018-08-10 | 2020-02-12 | Irbm S.P.A. | Tricyclic inhibitors of hepatitis b virus |
| CN113754685B (zh) * | 2020-06-02 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| CN113754678B (zh) * | 2020-06-02 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| US20230247994A1 (en) | 2020-07-02 | 2023-08-10 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
| CN115835863B (zh) * | 2020-07-09 | 2025-08-12 | 江苏恒瑞医药股份有限公司 | 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用 |
| JP2023536442A (ja) | 2020-07-29 | 2023-08-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用 |
| GB202117511D0 (en) * | 2021-12-03 | 2022-01-19 | Ionctura Sa | Treatment regimens |
| JP2024511836A (ja) | 2021-03-29 | 2024-03-15 | アイオンクチュラ・ソシエテ・アノニム | 膵臓癌の治療のためのｐｉ３ｋ－デルタ阻害剤 |
| EP4313058B1 (en) | 2021-03-29 | 2025-03-05 | iOnctura SA | Composition comprising roginolisib and dosage regime for treating cancer or an inflammatory or autoimmune disease |
| CN114524827B (zh) * | 2022-02-22 | 2024-07-09 | 深圳市儿童医院 | 一种用于治疗神经重症的吡唑衍生物及其应用 |
| CN114524828B (zh) * | 2022-02-22 | 2024-07-09 | 深圳市儿童医院 | 一种用于治疗神经重症的噻唑衍生物及其应用 |
| CN115491252B (zh) * | 2022-09-29 | 2023-05-02 | 江苏四新界面剂科技有限公司 | 一种宝石切割用低泡润湿剂及其制备方法 |
| CN121175043A (zh) | 2023-03-03 | 2025-12-19 | 伊昂克图拉股份有限公司 | 用于治疗血液恶性肿瘤的罗吉诺利西布与bcl-2抑制剂的组合 |
| CN120916756A (zh) | 2023-03-03 | 2025-11-07 | 伊昂克图拉股份有限公司 | 用于治疗血液恶性肿瘤的罗吉诺利西布与hdac抑制剂的组合 |
| GB202308807D0 (en) | 2023-06-13 | 2023-07-26 | Ionctura Sa | Combinations |
| WO2025073968A1 (en) | 2023-10-06 | 2025-04-10 | Ionctura Sa | Combination of roginolisib with a malt1-gls inhibitor |
| CN120682241A (zh) * | 2024-03-22 | 2025-09-23 | 复旦大学附属中山医院 | 三环骨架化合物及其在制备抗肿瘤药物中的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816467A (en) * | 1987-01-09 | 1989-03-28 | Farmitalia Carlo Erba S.R.L | Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use |
| GB8814586D0 (en) * | 1988-06-20 | 1988-07-27 | Erba Carlo Spa | Tricyclic 3-oxo-propanenitrile derivatives & process for their preparation |
| GB8907799D0 (en) * | 1989-04-06 | 1989-05-17 | Erba Carlo Spa | Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases |
| GB8916290D0 (en) * | 1989-07-17 | 1989-08-31 | Erba Carlo Spa | Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis |
| JP3542826B2 (ja) | 1994-07-11 | 2004-07-14 | 帝国臓器製薬株式会社 | 新規な二環式化合物縮合［２，１−ｄ］イソキサゾール−３−カルボン酸誘導体 |
| GB9720901D0 (en) * | 1997-10-01 | 1997-12-03 | Pharmacia & Upjohn Spa | Condensed benzothiopyranic compounds |
| FR2800375B1 (fr) * | 1999-11-03 | 2004-07-23 | Sanofi Synthelabo | Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| AU2003255528B2 (en) | 2002-07-10 | 2009-07-16 | Merck Serono Sa | Azolidinone-vinyl fused-benzene derivatives |
| BR0317572A (pt) | 2002-12-20 | 2005-11-22 | Warner Lambert Co | Benzoxazinas e seus derivados como inibidores de pi3ks |
| GB0305152D0 (en) | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| GB0320197D0 (en) | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
| RU2007116861A (ru) | 2004-10-07 | 2009-03-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | P13-киназы |
| US8324262B2 (en) | 2005-12-20 | 2012-12-04 | The Brigham And Women's Hospital, Inc. | Tricyclic necrostatin compounds |
| WO2008035356A2 (en) | 2006-09-20 | 2008-03-27 | Glenmark Pharmaceuticals Limited | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| WO2009010824A1 (en) * | 2007-07-13 | 2009-01-22 | Glenmark Pharmaceuticals, S.A. | Dihydrochromenopyrazole derivatives as vanilloid receptor ligands |
| WO2009071895A1 (en) * | 2007-12-04 | 2009-06-11 | Ucb Pharma S.A. | Fused thiazole and thiophene derivatives as kinase inhibitors |
| AR071112A1 (es) * | 2008-03-31 | 2010-05-26 | Genentech Inc | Derivados de benzopirano y benzoxepina inhibidores de quinasaspi3k, utiles como agentes anticancer,y composiciones farmaceuticas que los contienen. |
-
2010
- 2010-11-12 WO PCT/EP2010/067412 patent/WO2011058149A1/en not_active Ceased
- 2010-11-12 EA EA201290305A patent/EA201290305A1/ru unknown
- 2010-11-12 AR ARP100104189A patent/AR078979A1/es unknown
- 2010-11-12 US US13/509,291 patent/US9073940B2/en active Active
- 2010-11-12 CA CA2778174A patent/CA2778174C/en active Active
- 2010-11-12 MX MX2012005518A patent/MX2012005518A/es not_active Application Discontinuation
- 2010-11-12 ES ES10775841.9T patent/ES2607952T3/es active Active
- 2010-11-12 AU AU2010317883A patent/AU2010317883B2/en active Active
- 2010-11-12 CN CN201080061082.0A patent/CN102695710B/zh active Active
- 2010-11-12 KR KR1020127015183A patent/KR20130049766A/ko not_active Withdrawn
- 2010-11-12 EP EP10775841.9A patent/EP2499146B1/en active Active
- 2010-11-12 JP JP2012538350A patent/JP5735526B2/ja active Active
-
2012
- 2012-04-12 ZA ZA2012/02641A patent/ZA201202641B/en unknown
- 2012-05-06 IL IL219602A patent/IL219602A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013510825A5 (enExample) | ||
| JP2019094345A5 (enExample) | ||
| IL226912A (en) | The history of triazole, their preparation and their pharmaceutical preparations | |
| RU2015104123A (ru) | Производные пиримидинпиразолила | |
| JP2019500387A5 (enExample) | ||
| JP2016508505A5 (enExample) | ||
| JP2019034943A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2016518437A5 (enExample) | ||
| JP2016536364A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2018536648A5 (enExample) | ||
| JP2009534407A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| ME01294B (me) | Nova jedinjenja i kompozicije i metode upotrebe | |
| JP2019524883A5 (enExample) | ||
| JP2013514980A5 (enExample) | ||
| AR113826A1 (es) | Indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb) | |
| JP2013531031A5 (enExample) | ||
| RU2015137756A (ru) | Макроциклические производные пиридазинона | |
| JP2015531773A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| JP2016518434A5 (enExample) | ||
| JP2009534406A5 (enExample) | ||
| JP2016540742A5 (enExample) |